Claims
- 1. An isolated nucleic acid molecule consisting of nucleotides 440 to 1444 of SEQ ID NO: 1 wherein the nucleotide sequence comprises sequential nucleotide deletions from cither the C-terminus or the N-terminus.
- 2. An isolated polypeptide encoded by the polynucleotide of claim 1.
- 3. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 4. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 3.
- 5. A recombinant host cell produced by the method of claim 4.
- 6. The recombinant host cell of claim 5 comprising vector sequences.
- 7. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in testicular tissue of a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of SEQ ID NO: 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition in testicular tissue based on the presence or absence of said mutation.
- 8. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in testicular tissue of a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of SEQ ID NO:2 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide in normal and diseased testicular tissue.
- 9. A method of identifying a compound that modulates the biological activity of HGPRBMY26, comprising:
(a) combining a candidate modulator compound with HGPRBMY26 having the sequence set forth in SEQ ID NO:2; (b) measuring an effect of the candidate modulator compound on the activity of HGPRBMY26.
- 10. A method of identifying a compound that modulates the biological activity of HGPRBMY26, comprising:
(a) combining a candidate modulator compound with a host cell wherein HGPRBMY26 is endogenously expressed by the cell; and (b) measuring an effect of the candidate modulator compound on the activity of the endogenously expressed HGPRBMY26.
- 11. A cell capable of expressing the polypeptide of SEQ ID NO:2 either endogenously or recombinately, and a member selected from the group consisting of NFAT/CRE, and NFAT G alpha 15.
- 12. A method of screening for candidate compounds capable of modulating activity of the HGPRBMY26 polypeptide, comprising:
a.) contacting a test compound with the cell according to claim 11;b.) and selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 13. A compound that modulates the biological activity of human HGPRBMY26 as identified by the method according to claim 9, claim 10, or claim 12.
- 14. A pharmaceutical preparation comprising a therapeutically effective amount of the compound of claim 13 and a pharmaceutically acceptable carrier.
- 15. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of a member selected from the group consisting of:
a.) the polypeptide of claim 2;b.) the polynucleotide of claim 1;c.) the polypeptide provided as SEQ ID NO:2; d.) the polynucleotide provided as SEQ ID NO: 1; e.) the compound of claim 13; and f.) the pharmaceutical preparation of claim 14.
- 16. The method for preventing, treating, or ameliorating a medical condition of claim 15, wherein the medical condition is a member selected from the group consisting of a male reproductive condition; a condition wherein G-protein coupled receptors, either directly or indirectly, are involved in disease progression; an amine disorder wherein G-protein coupled receptors, either directly or indirectly, are involved in disease progression; a testicular disorder; testicular cancer; choriocarcinoma; nonseminoma; seminona; spermatogenesis; infertility; Klinefelter's syndrome; XX male; epididymitis; genital warts; germinal cell aplasia of the testis; cryptorchidism; varicocele; immotile cilia syndrome; viral orchitis; premature puberty; incomplete puberty; Kallman syndrome; Cushing's syndrome; hyperprolactinemia; hemochromatosis; congenital adrenal hyperplasia; FSH deficiency; and granulomatous disease.
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Ser. No. 60/273,963 filed Mar. 7, 2001; and to provisional application U.S. Ser. No. 60/278,927, filed Mar. 27, 2001. The entire teachings of the referenced applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60273963 |
Mar 2001 |
US |
|
60278927 |
Mar 2001 |
US |